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Inhibition of HIF-prolyl-4-hydroxylases prevents
mitochondrial impairment and cell death in a model of
neuronal oxytosis
S Neitemeier1, AM Dolga1, B Honrath1, SS Karuppagounder2,3, I Alim2,3, RR Ratan2,3 and C Culmsee*,1
Mitochondrial impairment induced by oxidative stress is a main characteristic of intrinsic cell death pathways in neurons
underlying the pathology of neurodegenerative diseases. Therefore, protection of mitochondrial integrity and function is emerging
as a promising strategy to prevent neuronal damage. Here, we show that pharmacological inhibition of hypoxia-inducible factor
prolyl-4-hydroxylases (HIF-PHDs) by adaptaquin inhibits lipid peroxidation and fully maintains mitochondrial function as indicated
by restored mitochondrial membrane potential and ATP production, reduced formation of mitochondrial reactive oxygen species
(ROS) and preserved mitochondrial respiration, thereby protecting neuronal HT-22 cells in a model of glutamate-induced oxytosis.
Selective reduction of PHD1 protein using CRISPR/Cas9 technology also reduced both lipid peroxidation and mitochondrial
impairment, and attenuated glutamate toxicity in the HT-22 cells. Regulation of activating transcription factor 4 (ATF4) expression
levels and related target genes may mediate these beneficial effects. Overall, these results expose HIF-PHDs as promising targets
to protect mitochondria and, thereby, neurons from oxidative cell death.
Cell Death and Disease (2016) 7, e2214; doi:10.1038/cddis.2016.107; published online 5 May 2016
Neurodegenerative diseases such asAlzheimer’s disease (AD),
Parkinson’s disease (PD) and stroke affect millions of people
in the ageing societies worldwide and, thus, are of great
clinical importance and scientific interest. Although they
widely differ in pathology and symptoms, neurodegenerative
diseases share common regulated pathways of neuronal cell
death underlying manifestation and progression of these
diseases. For example, enhanced oxidative stress has been
established as a common characteristic and key mediator of
neuronal demise.1–3 High amounts of reactive oxygen species
(ROS) caused by glutamate overload, toxic intracellular
Ca2+ concentrations or activation of lipoxygenases (LOX)4,5
induce oxidative damage of proteins and lipids at the plasma
membrane and in organelles, respectively, thereby leading to
regulated cell death.6 Mitochondria, in particular, have a
pivotal role in this cell death paradigm because they are
the key organelles in the energy metabolism and regulation
sites of ROS and apoptosis signaling pathways. Mitochondria
are major targets of ROS as their membranes and DNAs
are easily accessible and accordingly highly vulnerable to
oxidative stress.7 They also significantly contribute to the
additional formation of ROS when their own redox balance is
impaired.8 Upon damage, mitochondria release proapoptotic
proteins such as cytochrome c (Cytc), apoptosis-inducing
factor (AIF) and endonucleaseG,9,10 which leads to cell death.
Hence, it is well accepted that mitochondrial damage marks
the so-called ‘point of no return',10 meaning that cells with
impairedmitochondria cannot survive. Therefore, protection of
mitochondria is a promising strategy against neuronal
dysfunction and damage and, therefore, against the manifes-
tation and progression of neurodegenerative diseases.
Recently, hypoxia-inducible factor (HIF) prolyl-4-hydroxy-
lases (PHDs) emerged as promising target candidates
for mitochondrial protection in paradigms of oxidative stress.
The inhibition of HIF-PHDs prevented neuronal cell death
induced by mitochondrial toxins.11 In PHD1− /− myofibers
mitochondrial respiration in response to hypoxia was pre-
served owing to reduced oxidative stress.12
HIF-PHDs belong to a family of dioxygenases depending
on oxygen, iron and 2-oxoglutarate. They exist in the
three isoforms, PHD1, PHD2 and PHD3, and act as oxygen
sensors because of their main function being the regulation
of HIF expression levels.13 However, more and more
HIF-independent functions of HIF-PHDs11,14 and alternative
substrates15–17 have been recently identified, which are partly
isoform specific. Genetic approaches revealed reduced infarct
1Institut für Pharmakologie und Klinische Pharmazie, Biochemisch-Pharmakologisches Centrum Marburg, Fachbereich Pharmazie, Philipps-Universität Marburg, Karl-von-
Frisch-Straße 1, Marburg 35032, Germany; 2Burke-Cornell Medical Research Institute, White Plains, NY, USA and 3Feil Family Brain and Mind Research Institute,
Department of Neurology and Neuroscience, Weill Medical College, Cornell University, New York, NY, USA
*Corresponding author: C Culmsee, Institut für Pharmakologie und Klinische Pharmazie, Biochemisch-Pharmakologisches Centrum Marburg, Fachbereich Pharmazie,
Philipps-Universität Marburg, Karl-von-Frisch-Straße 1, Marburg 35032, Germany. Tel: +49 6421 2825780; Fax: +49 6421 2825720; E-mail: culmsee@staff.uni-marburg.de
Received 09.7.15; revised 23.2.16; accepted 22.3.16; Edited by C Munoz-Pinedo
Abbreviations: AD, Alzheimer’s disease; AIF, apoptosis-inducing factor; ANOVA, analysis of variance; ATF4, activating transcription factor 4; Bid, BH3-interacting domain
death agonist; CPO, Ciclopirox; Cytc, cytochrome c; DCF, 5,6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester; DFO, deferoxamine; DHB, ethyl-3,4-
dihydroxybenzoate; DMOG, dimethyloxalylglycine; eIF2α, eukaryotic initiation factor 2α; FACS, fluorescence-activated cell sorting; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; GSH, glutathione; HIF, hypoxia-inducible factor; HIF-PHD, HIF-prolyl-4-hydroxylase; LOX, lipoxygenase; MMP, mitochondrial membrane potential;
MnSOD, manganese superoxide dismutase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OCR, oxygen consumption rate; PD, Parkinson’s disease;
ROS, reactive oxygen species; TMRE, tetramethylrhodamine ethyl ester
Citation: Cell Death and Disease (2016) 7, e2214; doi:10.1038/cddis.2016.107
& 2016 Macmillan Publishers Limited All rights reserved 2041-4889/16
www.nature.com/cddis
volumes in PHD1− /− mice, and exposed improved behavior
and less neuronal cell death in the penumbra in PHD2+/− mice
in a model of transient focal cerebral ischemia.18 Further,
neuron-specific knockout of PHD2 confirmed neuroprotective
effects in the CA1 region after transient cerebral ischemia in
mice.19 Pharmacological inhibition of HIF-PHDs by iron
chelators or 2-oxoglutarate analogs also provided neuro-
protection in vitro and in vivo, in models of ischemic neuronal
death,20–22 AD,11,23 PD24–26 and Huntington’s disease,11
further supporting the pivotal role of HIF-PHDs in neuro-
degeneration.
To pursue this promising strategy, new HIF-PHD inhibitors
have been developed that are more selective than previously
available iron chelators such as deferoxamine (DFO)11,14,20
and ciclopirox (CPO).11 In particular, branched oxyquinolines
were identified to inhibit HIF-PHDs via coordination of iron at
the active site of HIF-PHDs and modeling shows little
predicted interaction with other 2-oxoglutarate-dependent
dioxygenases. Additionally, branched oxyquinolines exhibit
less iron-chelating properties than CPO,27 making it a useful
tool to study the effects of selective HIF-PHD inhibition. We
named this branched oxyquinoline molecule adaptaquin (AQ)
for its ability to inhibit the HIF-PHDs and activate adaptive
responses to hypoxia.27
In the present study, we investigated the effects of
AQ-mediated HIF-PHD inhibition and PHD1 gene silencing
on cell viability and, especially, mitochondrial integrity and
function in a model of neuronal oxytosis to elucidate the
mechanisms leading to AQ-mediated neuronal protection.
Oxytosis is defined as oxidative cell death in response to
glutamate toxicity, which induces a depletion of glutathione
(GSH) and subsequent formation of ROS, resulting in
mitochondrial demise and cell death. We found comparable
effects of AQ and PHD1 gene silencing on both mitochondrial
function and cell viability, suggesting a crucial role for HIF-
PHDs in mitochondrial impairment and subsequent neuro-
degeneration induced by oxidative stress.
Results
PHD1 gene silencing attenuates oxytosis and restores
mitochondrial function. In HT-22 cells, high concentrations
of extracellular glutamate induce lethal oxidative stress.28
This cell death paradigm is known as oxytosis and is
characterized by significant morphological and metabolic
changes, for example, GSH depletion or activation of LOX.29
To study the role of PHD1 in this model system of lethal
oxidative stress, we used CRISPR/Cas9 technology to
create cells with reduced expression of PHD1 protein. From
the initial screening two clones were selected, referred to as
clone 2.17 and clone 5.18 below. Western blot analysis
(Figure 1a) and subsequent quantification (Figure 1b)
revealed significant downregulation of PHD1 protein in both
clones compared with wild-type (WT) HT-22 cells. We further
analyzed the effects of this downregulation of PHD1 on cell
viability and mitochondrial function. PHD1 silencing attenu-
ated glutamate-induced loss of cell viability indicated by MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay (Figure 1c). This protective effect was permanent at
least for 14 h of the recording, as further detected by real-time
measurements of cellular impedance (Figure 1d).
In themodel system of oxytosis, enhanced lipid peroxidation
is regarded as a trigger for mitochondrial damage.30 Hence,
we examined the formation of lipid peroxides after PHD1 gene
silencing in the presence and absence of glutamate. BODIPY
staining and consequent fluorescence-activated cell sorting
(FACS) analysis revealed that PHD1 downregulation pre-
vented lipid peroxidation upon glutamate treatment and
did not affect basal levels of lipid ROS (Figure 2a). As it is
well established that mitochondrial demise due to elevated
ROS levels is a hallmark of oxytosis,30,31 mitochondrial ROS
formation was then analyzed. To this end, WT HT-22 cells,
Figure 1 Silencing PHD1 by CRISPR/Cas9 attenuates oxytosis. (a) Selective
knockdown of PHD1 by CRISPR/Cas9 was verified by western blot analysis. (b)
Quantification of four independent western blots shows a reduction of PHD1 protein
level. (c) MTT assay reveals protection of the downregulation of PHD1 by CRISPR/
Cas9 (clones 2.17 and 5.18) against glutamate toxicity (5 mM, 16 h) compared with
WT cells. Data are given as mean± S.D. (n= 8). ###Po0.001 compared with
untreated WT control; **Po0.01 and ***Po0.001 compared with glutamate-treated
WT control (ANOVA, Scheffé's test). (d) xCELLigence real-time measurement:
downregulation of PHD1 by CRISPR/Cas9 (clones 2.17 and 5.18) shows protection
against treatment with 7 mM glutamate (glut) compared with WT cells
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clone 2.17 and clone 5.18 were treated with glutamate and
stained with MitoSOX. Subsequent FACS analysis showed an
increase in mitochondrial superoxide formation, which was
significantly abolished by PHD1 downregulation (Figure 2b).
As previously described in this system of glutamate toxicity
in HT-22 cells,32,33 the oxidative cell death is associated with
a breakdown of mitochondrial membrane potential (MMP).
Measurement of MMP revealed a reduction of mitochondrial
Figure 2 PHD1 silencing by CRISPR/Cas9 restores mitochondrial function and prevents ROS formation. (a) Cells were stained with BODIPY 581/591, a lipophilic fluorescent
dye that undergoes a shift from red to green fluorescent emission upon oxidation by free radicals and therefore correlates with the formation of lipid peroxides. Changes of
fluorescence were detected by FACS analysis after 15 h of glutamate treatment (7 mM). Clones 2.17 and 5.18 showed a significant reduction of the lipid peroxide production
compared with WT control cells (n= 4). (b) Mitochondrial ROS production was detected by MitoSOX staining and following FACS analysis. Glutamate treatment (7 mM, 15.5 h)
led to an increase in ROS production. Downregulation of PHD1 by CRISPR/Cas9 (clones 2.17 and 5.18) reduced this increase. Quantification of MitoSOX fluorescence of n= 4
independent experiments. Data are shown as mean± S.D. ###Po0.001 compared with untreated WT control; ***Po0.001 compared with glutamate-treated WT control
(ANOVA, Scheffé's test). (c) Representative FACS plots showing that MMP measured by TMRE fluorescence is restored by downregulation of PHD1 by CRISPR/Cas9 (clones
2.17 and 5.18) after glutamate exposure (6 mM, 15.5 h). (d) After 15.5 h of treatment with glutamate (7 mM), ATP levels were measured. PHD1 silencing by CRISPR/Cas9
(clones 2.17 and 5.18) prevented glutamate-induced ATP depletion (n= 8). Data are shown as mean± S.D. ###Po0.001 compared with untreated WT control; ***Po0.001
compared with glutamate-treated WT control. (ANOVA, Scheffé's test)
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depolarization by selective PHD1 silencing indicated by
restored tetramethylrhodamine ethyl ester (TMRE) fluores-
cence (Figure 2c). These findings correlated well with the
corresponding effects on cell viability. Further, we observed a
pronounced loss of ATP after onset of glutamate, which was
fully abolished by PHD1 gene silencing (Figure 2d).
To exclude off-target effects, we used siRNA approaches
to transiently knockdown PHD1 and performed the same set
of experiments. PHD1 siRNA sequences I and II (siPHD I and
siPHD II) significantly decreased the mRNA levels of PHD1,
while the downregulation at the protein level was not as
pronounced (as shown in the western blot in Supplementary
Figure 1a). The effect of the siRNAs on PHD1 protein was
smaller than the one achieved by the CRISPR/Cas9 techno-
logy. Quantification of western blots of five independent
experiments confirmed a regulatory effect of the siRNA
sequences targeting PHD1 at the protein level, and also
showed a high variation of gene silencing efficacy (Supple-
mentary Figure 1b). This partial siRNA-mediated PHD1
downregulation attenuated glutamate-induced loss of cell
viability indicated by MTT assay (Supplementary Figures 1c
and d). Opposed to the findings in clone 2.17 and 5.18, but in
line with the partial downregulation of the PHD1 protein, this
protective effect was only transient when detected by real-
time measurement of cellular impedance (Supplementary
Figures 1e and f). However, knockdown of PHD1 by siRNA
approaches attenuated all hallmarks of glutamate-induced
oxidative cell death in HT-22 cells, such as the formation of
mitochondrial and lipid peroxides, the breakdown of MMP and
loss of ATP (Supplementary Figure 2).
AQ protects against glutamate-induced cell death. To
further investigate the effects of HIF-PHD inhibition during
oxytosis, we used the pharmacological selective HIF-PHD-
inhibitor AQ.27 The glutamate challenge induced established
morphological hallmarks of cell death, that is, the cells shrink,
round up and detach from the bottom of the culture dish.
Cotreatment with AQ fully prevented these morphological
features of cell death (Figure 3a) and preserved cell viability
as detected by the MTT assay (Supplementary Figure 3a). A
dose-dependent protective effect of AQ was further detected
using the xCELLigence system (Roche, Penzberg, Germany;
Figure 3b). To establish a therapeutic time window for AQ
in the paradigm of glutamate-induced oxytosis, we treated
HT-22 cells with the HIF-PHD inhibitor 2 at 4, 6, 8 and 10 h
following the onset of glutamate. Real-time recordings of the
cellular impedance demonstrated full protection against
oxytosis by post-treatment with AQ up to 4 h after the onset
of glutamate exposure (Supplementary Figure 3b). Notably,
even 10 h after the onset of glutamate, AQ was able to rescue
a significant part of the cells (Figure 3c), indicating a very
strong neuroprotective potential of this particular HIF-PHD
inhibitor with an extended post-treatment window of up to
10 h after onset of oxidative stress.
Glutamate-induced calcium influx is a late-stage event
during oxytosis.34 Under conditions of extracellular calcium
depletion, AQ was still able to prevent glutamate-induced cell
death (Supplementary Figure 3c). This observation indicates
that AQ does not act via a chelation of calcium and underlines
its target specificity.
To confirm the protective effect of HIF-PHD inhibition in
the model system of neuronal oxytosis, we next applied
different inhibitors of HIF-PHDs, including the 2-oxoglutarate
analog ethyl-3,4-dihydroxybenzoate (DHB: 0.1–50 μM) as
well as the iron chelators DFO (0.1–100 μM) and CPO
(1–20 μM). All HIF-PHD inhibitors tested protected HT-22
cells against glutamate-induced oxytosis in a similar manner
as AQ, which was indicated by preserved cell viability
(Figures 3d–f).
AQ preserves mitochondrial respiration. Mitochondria
are known to have a key role in cellular life and death,
because they are the main source of energy supply,
regulation sites for ROS production and key control points
for intrinsic pathways of apoptosis.35 Impaired energy
metabolism due to mitochondrial damage is reflected by
reduced ATP levels and loss of MMP, which are regarded
as hallmarks of neuronal cell death.1,10 To correlate the
observed neuroprotective properties of AQ with restored
mitochondrial function, we examined the mitochondrial
respiratory capacity and ATP production by measuring the
oxygen consumption rate (OCR) using the Seahorse XF96
system (Seahorse Biosciences, North Billerica, MA, USA).
The glutamate challenge decreased both the basal and
maximal respiration reflected by a reduced OCR. These
detrimental metabolic changes were abolished by cotreat-
ment with AQ (Figure 4a), which, furthermore, restored the
mitochondrial ATP production (Figure 4b).
Owing to the very pronounced effect of AQ on cell viability, as
well as mitochondrial integrity, we were interested to find out if
this particular HIF-PHD inhibitor was capable of preventing
glutamate-inducedGSHdepletion, which is the starting point of
oxidative stress and oxytosis. To this end, we examined the
levels of GSH after the glutamate challenge in the presence
and absence of AQ. Similar to previous findings,29,34 glutamate
(5 mM) induced a rapid and sustained decrease of GSH levels
within 2 h and up to 10 h of exposure. Notably, wewere not able
to detect GSH levels in HT-22 cells after 10 h of glutamate
exposure because the GSH levels dropped below detection
limits. Surprisingly, although AQ fully protected HT-22 cells
from cell death and morphological changes, it failed to rescue
the observed drop of GSH levels (Figure 4c). These findings
indicated that HIF-PHD inhibition provided neuroprotective
effects downstream of GSH depletion, and GSH restauration
was dispensable for the protective effects.
The other aforementioned HIF-PHD inhibitors exhibited
similar effects upstream and at the level of mitochondria as
observed for AQ. DFO, DHB and CPO prevented glutamate-
induced lipid peroxidation (Figure 5a) and subsequent
formation of mitochondrial ROS (Figure 5b), while none of
the inhibitors affected any of these parameters under basal
conditions. Furthermore, DFO, DHB and CPO fully restored
ATP levels (Figure 5c) and the MMP examined via TMRE
staining (Figure 5d). Similar to the effects obtained with AQ,
DFO, DHB and CPO also maintained both, basal and maximal
mitochondrial respiration (Figure 5e). These observations
suggest an almost intact mitochondrial function upon inhibition
of HIF-PHDs in the presence as well as in the absence of
glutamate, which correlates well with the observed protection
of cell viability.
Inhibition of HIF-PHDs prevents mitochondrial demise
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AQ shows antioxidative properties independent of
MnSOD. As GSH is the main antioxidant in the brain, it
has a crucial role for detoxification of ROS and a disturbed
GSH metabolism has been associated with neurodegenera-
tive diseases.36 The question arose of how can AQ mediate
neuroprotection despite impaired GSH levels. To address
this question, we analyzed the formation of soluble ROS 6 h
after the onset of glutamate treatment to identify possible
antioxidative characteristics of AQ. To this end, HT-22 cells
were stained with CM-H2DCFDA (5,6-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate acetyl ester), a fluores-
cent dye that shows green fluorescence upon oxidation by
soluble ROS. After 6 h of glutamate exposure, we saw an
increase in green fluorescence, indicating enhanced forma-
tion of ROS (Figure 6a), which correlates well with the results
of the GSH measurements. Hence, AQ reduced this effect,
but was not able to fully abolish it (Figure 6b). This suggests
some antioxidative properties, which were further supported
Figure 3 PHD inhibitors protect against oxytosis. (a) Light microscopy pictures show altered morphology of glutamate-treated (5 mM, 15 h) HT-22 cells. Cotreatment with AQ
(2 μM) fully prevents these changes. Scale bar: 50 μm. (b) xCELLigence real-time impedance measurement shows dose-dependent salutary effect of AQ (n= 6). (c) Bar graph
evaluation at the 15.5 h time point from xCELLigence recordings (Supplementary Figure 3b, right black arrow) under post-treatment conditions (n= 6). ###Po0.001 compared
with untreated control; *Po0.05 and ***Po0.001 compared with glutamate-treated control (ANOVA Scheffé’s test). (d–f) MTT assays show protective effects of different
concentrations of DFO (d), DHB (e) and CPO (f) against glutamate-induced (7 mM, 16 h) oxytosis (n= 8). Data are given as mean± S.D. ###Po0.001 compared with untreated
control; ***Po0.001 compared with glutamate-treated control (ANOVA Scheffé’s test)
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by a dose-dependent protection against H2O2-induced cell
death (Figure 6c). However, these partial antioxidative effects
cannot fully explain the mitochondrial protection, and, there-
fore, we also checked for changes in the expression of the
manganese superoxide dismutase (MnSOD). MnSOD is
known to be part of the antioxidative defense of mitochondria
and its overexpression has been shown to reduce oxidative
damage in HT-22 cells.28 Interestingly, glutamate induced
a strong increase in MnSOD levels while they remained
almost unchanged after treatment with AQ (Supplementary
Figure 4a). Thus, suggesting that AQ does not mediate
protection against glutamate by enhancing the antioxidative
defense machinery of mitochondria. The glutamate-induced
upregulation of MnSOD indicates a compensatory effect of
the damaged cells to cope with enhanced oxidative stress.37
AQ alters ATF4 expression. As ATF4 has been shown to
correlate with oxidative stress38,39 and also to regulate and
interact with HIF-PHDs,40,41 we examined the expression of
ATF4 upon glutamate exposure to further elucidate the
mechanism of AQ-mediated protection. ATF4 expression
increased 4 h after the onset of glutamate treatment and
decreased at 14 h. This downregulation associated with
glutamate-induced death was fully prevented by HIF-PHD
inhibition (Figure 7a). A similar expression pattern after 14 h
of glutamate exposure was found for the xCT, which was
recently shown to be regulated by ATF4 in HT-22 cells.42 After
14 h of glutamate treatment, xCT levels declined, while
cotreatment with AQ restored xCT expression levels at this
time point (Figure 7b). To determine if the regulation of xCT
was driven via the eukaryotic initiation factor 2α (eIF2α)/ATF4
pathway, we investigated the phosphorylation state of
eIF2α at both 4 and 14 h after the onset of the glutamate
treatment. The phosphorylation of eIF2α seemed to be
transiently enhanced at 4 h in the presence of AQ irrespective
of glutamate exposure. After 14 h, none of the treatment
conditions induced significant changes in the phosphorylation
state of eIF2α (Figure 7c). Overall, these data imply that the
alterations in xCTexpression levels may be mediated through
ATF4, but are not induced via the eIF2α/ATF4 pathway.
ATF4 expression is not required for AQ-mediated protec-
tion. To answer the question of whether the restoration of
ATF4 expression induced by AQ after 14 h of glutamate
challenge was required for the protective effect, we analyzed
cell viability after siRNA-mediated gene silencing of ATF4.
Surprisingly, AQ still protected ATF4-silenced cells against
Figure 4 AQ preserves mitochondrial respiration. (a) Measurement of the
OCR reveals restored basal and maximal respiration by AQ (2 μM) after glutamate
exposure (4 mM, 15 h). (b) Quantification of ATP production from (a) calculated as
difference between average OCR in section A (light gray) and section B (white)
shows loss of ATP after glutamate exposure. AQ prevents decrease of ATP
levels (n= 6). Data are given as mean±S.D. ###Po0.001 compared with
untreated control; ***Po0.001 compared with glutamate-treated control
(ANOVA Scheffé’s test). (c) Measurement of GSH depicts rapid decrease of GSH
after glutamate exposure (5 mM), which is not restored by cotreatment with
AQ (2 μM)
Figure 5 PHD inhibitors preserve mitochondrial function and prevent generation of mitochondrial and lipid peroxides. (a) DFO (20 μM), DHB (20 μM) and CPO (2 μM)
abolish glutamate-induced (7 mM, 15 h) formation of lipid peroxides measured by BODIPY staining and subsequent FACS analysis. Data are given as mean±S.D. (n= 4).
###Po0.001 compared with untreated control; ***Po0.001 compared with glutamate-treated control (ANOVA Scheffé’s test). (b) DFO (20 μM), DHB (20 μM) and CPO (2 μM)
prevent generation of mitochondrial ROS upon glutamate treatment (7 mM, 15 h). Data are given as mean± S.D. ###Po0.001 compared with untreated control; ***Po0.001
compared with glutamate-treated control (ANOVA Scheffé’s test). (c) Different concentrations of DFO, DHB and CPO prevent glutamate-induced (7 mM, 15 h) loss of ATP. Data
are given as mean±S.D. (n= 8). ###Po0.001 compared to untreated control; ***Po0.001 compared to glutamate-treated control; ANOVA Scheffé’s test. (d) DFO (20 μM),
DHB (20 μM) and CPO (2 μM) fully prevent breakdown of MMP after glutamate challenge (7 mM, 15 h). Data are given as mean±S.D. (n= 4). ###Po0.001 compared with
untreated control; ***Po0.001 compared with glutamate-treated control; ANOVA Scheffé’s test. (e) Measurement of the OCR after glutamate exposure (4 mM, 15 h) shows
decrease of the basal and maximal respiration, which was prohibited by DFO (20 μM), DHB (20 μM) and CPO (2 μM), respectively
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glutamate-induced cell death. Notably, siRNA-mediated ATF4
downregulation itself resulted in pronounced cytotoxicity,
which was completely abolished by AQ (Figures 8a and b).
Such toxic effects by ATF4 gene silencing can likely be
attributed to the enhanced formation of soluble ROS, which
occurred in a time-dependent manner in HT-22 cells after
Inhibition of HIF-PHDs prevents mitochondrial demise
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incubation with ATF4 siRNA (Figure 8c). Cotreatment with AQ
during transfection prevented this formation of ROS by ATF4
silencing (Figure 8d). Overall, these data suggest that the
observed AQ-mediated upregulation of ATF4 was dispensa-
ble for the protective effect of the HIF-PHD inhibitor.
Discussion
The present study clearly depicts that both pharmacological
inhibition and gene silencing of HIF-PHDs prevent
mitochondrial impairment and cell death in a model of
neuronal oxytosis. Our results on cell viability confirm previous
findings for PHD1 silencing and the HIF-PHD inhibitors DFO,
DHB and CPO in similar models of neuronal oxidative
stress.14,20,43 Protective effects of DFO and dimethyloxalyl-
glycine (DMOG) against glutamate toxicity, and of DFO, DHB
and CPO against 3-nitropropionic acid,11 were previously also
obtained in HIF-1α-silenced cells.14,44 Beyond previous
findings, our study now demonstrates that HIF-PHD inhibitors
exert protective effects at the level of mitochondria. Results
from previous studies suggest that HIF-1α-independent
mechanisms contribute to the protection of mitochondria.
The identification of additional targets of HIF-PHDs besides
HIF-1α, such as the large subunit of RNA polymerase II16 and
cyclin D1,17 and the presence of HIF-PHDs in organisms not
expressing HIF isoforms further support the conclusion of HIF-
independent functions of HIF-PHDs.45 Moreover, HIF-1α is
predominantly regulated by PHD2.46 Nevertheless, in our
system we achieved both the protection of cell viability and
mitochondrial integrity by silencing PHD1 without regulating
the mRNA level of PHD2 (Supplementary Figure 1a), which
facilitated an HIF-independent mechanism of protection.
Further, Aragonés et al.12 also showed that PHD1 deficiency
reduced the formation of oxidative stress and preserved
mitochondrial function after ischemia in skeletal muscle fibers,
thereby leading to hypoxia tolerance independently of HIF-
induced adaptive effects.
The conservation of mitochondrial function as a crucial
mechanism of neuronal protection has widely been shown in
AD47 and PD48 models as well as in humans.49 Our present
data suggest that mitochondrial protection also has a central
role in AQ- and PHD1 CRISPR/Cas9- or siRNA-mediated
protection of HT-22 cells. During oxidative stress, mitochon-
drial demise is induced by the transactivation of the
proapoptotic protein BH3-interacting domain death agonist
(Bid) via ROS.9 In HT-22 cells, these ROS result from lipid
peroxidation5,30 due to GSH depletion.34 Both silencing PHD1
and AQ abolished the formation of lipid peroxides, indicating
an action upstream of mitochondria and leading to mitochon-
drial protection. Despite the pronounced neuroprotective
effect, AQ was unable to prevent the glutamate-induced
decrease of GSH levels below detection limits. This observa-
tion is in line with previous findings where full protection of
HT-22 cells was achieved despite fully depleted GSH
levels.34,50 Taken together, these results suggest an influence
of HIF-PHD inhibition by AQ at the level of 12/15-LOXs. This
can not only be explained by the iron-chelating effects or off-
target inhibition of these enzymes, as PHD1 gene silencing
also reduced lipid peroxidation (Figure 2a and Supplementary
Figure 2a). Further, structural analyses revealed that AQ did
not fit to the active center of 12-LOX.27 A possible explanation
for the activity of HIF-PHD inhibition on LOX activities was
recently provided by Karuppagounder and Ratan51 who
proposed a suppression of 12-LOX expression upon inhibition
of HIF-PHDs. This suppression has been attributed to
modification of RNA polymerase II.51 Downregulation of
12/15-LOX expression after both AQ treatment and PHD1
knockdown further facilitated this assumption (Supplementary
Figures 4b–d).
Figure 6 AQ shows small antioxidative properties. (a) DCF staining shows
formation of soluble ROS after 6 h of glutamate (4 mM) challenge. Cotreatment with
AQ (2 μM) reduces soluble ROS. (b) Quantification of DCF fluorescence of n= 3
independent experiments shown in the representative plots in (a). Data are shown as
mean± S.D. ###Po0.001 compared with untreated control; ***Po0.001 compared
with glutamate-treated control; ANOVA, Scheffé‘s test. (c) MTT assay shows dose-
dependent protection of AQ against H2O2-induced cell death (16 h). Data are shown
as mean±S.D. (n= 8). ###Po0.001 compared with untreated control; ***Po0.001
compared with respective H2O2-treated control; (ANOVA, Scheffé's tes)
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In our system, both PHD1 gene silencing by CRISPR/Cas9
and the use of pharmacological approaches permanently
protected HT-22 cells. In contrast, knockdown of PHD1 by
siRNA only showed partial protective effects. Apparently, the
transient knockdown via siRNA results in a residual activity
of the enzyme, which is sufficient enough to promote cell
death. Further, inhibition of PHD1 may improve oxygen
radical detoxification and accordingly reduced detection of
lipoxygenation through shunting glucose into the pentose
phosphate pathway, as recently demonstrated in PHD1− /−
neurons and in a model of cerebral ischemia in vivo.52 Further
studies should reveal whether such reprogramming of the
glucose metabolism is also involved in the protective effects of
AQ and other PHD inhibitors in paradigms of oxidative cell
death and at the level of mitochondria.
The pharmacological HIF-PHD inhibitors do not act on
specific isoforms of the enzyme, suggesting that also inhibition
of PHD2 and PHD3 may contribute to the protective effects of
Figure 7 AQ regulates ATF4 expression. (a) Representative western blots and corresponding quantifications of four independent experiments show upregulation of ATF4
after 4 h of glutamate and downregulation after 14 h, which is restored by AQ. #Po0.05 compared with glutamate-treated control. (b) Representative western blots and
corresponding quantifications of four independent experiments reveal upregulation of xCTafter 4 h of glutamate and downregulation after 14 h, which is restored by AQ. *Po0.05
and **Po0.01 compared with untreated control. (c) Representative western blots and corresponding quantification do not indicate significant changes of the phosphorylation
state of eIF2α upon glutamate challenge or treatment with AQ
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the pharmacological HIF-PHD inhibitors against glutamate-
induced cell death. However, knockdown of PHD1 by
CRISPR/Cas9 was just as effective inferring that PHD2 and
PHD3 do not have a significant role during oxytosis. This
assumption is in line with previous findings where knockdown
of both isoforms did not abolish oxidative-stress-induced
death in cortical neurons.14 In contrast, overexpression of
PHD3 (but not PHD1 or PHD2) induces apoptosis in PC12
cells53 and also enhanced the expression of SM-20, a rat
orthologue of PHD3 that promotes cell death in PC12 cells54
and sympathetic neurons,55 indicating a proapoptotic function
of PHD3.
PHD1 and PHD3 have been shown to regulate and interact
with ATF4,40,41 a transcription factor displaying both
antiapoptotic56,57 and proapoptotic properties,38,58 depending
on the cellular system and experimental settings. According to
observations of Köditz et al.41 DMOG and siRNA-mediated
PHD3 gene silencing stabilized ATF4 expression under
Figure 8 ATF4 silencing does not diminish AQ-mediated protection. (a) Representative dot plots show cell death after glutamate challenge (6 mM, 25 h) analyzed by AV/PI
staining and subsequent FACS analysis. (b) Quantification of AV- and AV/PI-positive cells from the plots in (a) (n= 3). Data are shown as mean± S.D. ###Po0.001 compared
with untreated siScr; ***Po0.001 compared with glutamate-treated siScr (ANOVA, Scheffé's test). (c) Quantification of DCF staining reveals time-dependent formation of soluble
ROS after ATF4 gene silencing. Data are shown as mean± S.D (n= 4). ***Po0.001 compared with respective vehicle. (d) Cotreatment with AQ prevents generation of soluble
ROS after ATF4 knockdown revealed by DCF staining and subsequent FACS analysis. Data are given as mean± S.D. (n= 3). ###Po0.001 compared with respective untreated
vehicle; ***Po0.001 compared with respective untreated siATF4
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normoxic conditions in HeLa cells.41 In the present study, AQ-
mediated HIF-PHD inhibition restored ATF4 levels after the
glutamate challenge. These data, together with the observed
toxic effects of ATF4 downregulation, suggest an antiapoptotic
function of ATF4 in HT-22 cells. This conclusion is in line with
previous findings, where an overexpression of ATF4 protected
against glutamate toxicity.42 In contrast to the present data,
this protection was mediated by an ATF4-dependent upregu-
lation of the xCT via the eIF2α pathway and subsequent
restoration of GSH levels.39 AQ also maintained xCT levels
after glutamate exposure. However, this neither correlated
with the phosphorylation of eIF2α nor restored GSH levels,
suggesting that this pathway was not essential to mediate
protection by AQ. In this study, AQ even protected ATF4-
silenced HT-22 cells from oxytosis and reduced the formation
of soluble ROS generated by ATF4 downregulation. This
corresponds with earlier results using ATF4− /− cells cultured
in the absence of reducing agents where DFO increased the
survival, presumably because of the diminished formation of
ROS.57 All in all, these data imply that, despite potential
protective effects of ATF4, the regulation of this transcription
factor was dispensable for AQ-mediated protection. Overall,
transcriptional regulation by AQ was unlikely the dominating
mechanism of action in the present paradigm of oxytosis, as
AQ-mediated protection even when applied 10 h after the
onset of glutamate exposure.
In conclusion, the present study introduces inhibition of HIF-
PHDs as an eligible and promising target to abolish
mitochondrial impairment and subsequent neuronal death.
The current data suggest that both AQ and selective PHD1
gene silencing act upstream of mitochondria. The mechanism
by which AQ prevents glutamate-induced oxidative stress
includes multimodal regulations of enzymes involved in the
regulation of oxidative stress that are independent of HIF-1α
regulation.
Materials and Methods
Cell culture. HT-22 cells were cultured in Dulbecco’s modified Eagle’s medium
with the addition of 10% heat-inactivated fetal calf serum, 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM glutamine.
For inducing cell death, 3–7 mM glutamate or 600–800 μM H2O2 was added to the
medium for the indicated amount of time.
SiRNA transfections were performed by using Lipofectamine RNAiMax (Invitrogen,
Karlsruhe, Germany) following the manufacturer’s protocol. After complex formation,
an adequate number of cells was added in antibiotic-free medium to the transfection
mix according to the following experimental procedure. Cells were treated after
growing for 48 h. The following siRNA sequences were used: 5′-AUCGAAGUCAAAC
UCUUUCUU-3′ (ATF4), 5′-CAGUGUGGCUGGCGGUCAU-3′ (PHD1 siRNA II),
5′-GCCAUCACUGUCUGGUAUU-3′ (PHD1 siRNA I), 5′-UAAUGUAUUGGAACGC
AUA-3′ (scrambled siRNA). AQ, DFO, DHB and CPO were dissolved in DMSO.
Generation of HT-22 cells with reduced PHD1 protein levels. WT
HT-22 cells were seeded in 6-well plates at a density of 100 000 cells/well, and after
24 h, transfected with 5 μg PHD1 CRISPR plasmid (U6gRNA-Cas9-2 A-GFP;
MM0000478768, Sigma-Aldrich, Taufkirchen, Germany) using 4.5 μl Attractene and
up to 250 μl OptiMEM/well. Two days later, transfection efficiency was confirmed by
fluorescence microscopy and cells harvested with trypsin. Afterwards, cells were
sorted via FACS and one, two or five cells seeded into a 96-well plate. To exclude
dead cells, cells were costained with DAPI. Cells were cultured with weekly media
change to obtain appropriate amount of cells for further analysis. Clone 2.17 was
derived from initial seeding with two cells per well and clone 5.18 from five cells
per well.
Cell viability. Cytotoxicity and cell viability were quantified by the MTT assay.
After induction of cell death by glutamate for indicated time of treatment, MTT was
added in a final concentration of 0.5 mg/ml to the culture medium. For calcium
chelation experiments, the culture medium with or without extracellular calcium was
prepared with indicated EGTA concentrations. In case of H2O2 treatment, the culture
medium was removed after induction of cell death and replaced by PBS containing
0.5 mg/ml MTT. Cells were incubated for 1 h at 37 °C. The resulting purple formazan
was dissolved in an appropriate amount of DMSO and absorbance measured at 570
versus 630 nm with FluoStar (BMG Labtech, Ortenberg, Germany).
For real-time measurement of cell viability, the xCELLigence system was used as
described previously.59
Additionally, cell viability after ATF4 gene silencing was detected by an Annexin
V/propidium iodide (AV/PI) staining using an Annexin-V-FITC Detection Kit
(Promokine, Heidelberg, Germany) followed by FACS analysis. Annexin-V-FITC
was excited at 488 nm and emission was detected through a 525/30 bandpass filter.
Propidium iodide was excited at 488 nm and fluorescence emission was detected
using a 690/50 bandpass filter. Data were collected from 10 000 cells from at least
three wells per condition.
RT-PCR. Forty-eight hours after siRNA transfection, total RNA amount was
extracted by InviTrap Spin Universal RNA Kit (Stratec Molecular, Berlin, Germany).
RT-PCR was performed with SuperScript III One-Step RT-PCR Kit with Platinum Taq
(Invitrogen). The following primers were used: PHD1: forward, 5′-TTGCCTGGGTAG
AAGGTCAC-3′ and reverse, 5′-GCTCGATGTTGGCTACCACT-3′; PHD2: forward,
5′-AGCCATGGTTGCTTGTTACC-3′ and reverse, 5′-CTCGCTCATCTGCATCAAAA-3′;
GAPDH (glyceraldehyde 3-phosphate dehydrogenase): forward, 5′-AGGCCGGTG
CTGAGTAT-3′ and reverse, 5′-TGCCTGCTTCACCACCTTCT-3′. DNA products
were visualized on a 1% agarose gel by UV illumination.
Protein analysis and western blot. Forty-eight hours after siRNA
transfection or after the indicated time of glutamate challenge, cells were washed
once with PBS and lysed with buffer containing 0.25 M mannitol, 0.05 M Tris, 1 M
EDTA, 1 M EGTA, 1 mM DTT, 1% Triton-X, supplemented with Complete Mini
Protease Inhibitor Cocktail and PhosSTOP (both Roche Diagnostics, Penzberg,
Germany). Extracts were centrifuged at 10 000xg for 15 min at 4 °C to eliminate
insoluble fragments. The total amount of protein was determined by Pierce BCA
Protein Assay Kit (Perbio Science, Bonn, Germany). For western blot analysis,
40–60 μg of protein were loaded on a 12.5% SDS gel and blotted onto a PVDF
membrane at 20 mA for 21 h. Incubation with primary antibody was performed
overnight at 4 °C. The following primary antibodies were used: anti-PHD1 (Novus
Biologicals, Littleton, CO, USA) 1:1 000 in 0.5% IBLOCK, anti-superoxide
dismutase 2 (Novus Biologicals) 1:1 000 in 5% skim milk, anti-ATF4 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) 1:500 in 0.5% IBLOCK, anti-xCT (Abcam,
Cambridge, UK) 1:1 000 in 5% BSA, anti-eIF2α (Cell Signaling, Danvers, MA, USA)
1:1 000 in 5% BSA, anti-phospho-eIF2α (Cell Signaling) 1:500 in 5% BSA, anti-15-
LOX 1 1:500 in 0.5% IBLOCK (Abcam) and anti-actin C4 (MB Biomedicals, Illkirch,
France) 1:10 000 in 5% skim milk. After incubation with proper secondary HRP-
labeled antibody (Vector Laboratories, Burlingame, CA, USA), western blot signals
were detected by chemiluminescence with Chemidoc software (Bio-Rad, Munich,
Germany) and quantified with the Quantity One software (Bio-Rad).
Mitochondrial ROS formation. Formation of mitochondrial ROS was
investigated via MitoSOX red staining (Invitrogen), which shows increasing red
fluorescence upon reaction with mitochondrial ROS. For analysis of PHD inhibitors,
HT-22 cells were seeded in 24-well plates with 55 000 cells per well. For functional
analysis of PHD1 siRNAs, cells were transfected with 22 000 cells per well and
grown for 48 h before treatment. At indicated time points after onset of treatment,
cells were stained with MitoSOX red for 30 min at 37 °C at a final concentration of
2.5 μM. After collecting and washing once with PBS, cells were resuspended in an
appropriate amount of PBS and red fluorescence was detected by FACS analysis.
MitoSOX red was excited at 488 nm and emission was recorded using a 690/50
bandpass filter. Data were collected from 10 000 cells from at least three wells per
condition.
Mitochondrial membrane potential. For the analysis of changes in the
MMP after glutamate exposure, the MitoPT ΔΨm Kit (Immunochemistry
Technologies, Hamburg, Germany) was used. For the analysis of HIF-PHD
inhibitors, HT-22 cells were seeded in 24-well plates with 55 000 cells per well. For
functional analysis of PHD1 siRNAs, cells were transfected with 22 000 cells per
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well and grown for 48 h before treatment. After glutamate challenge, in particular,
HIF-PHD inhibition cells were collected and stained with TMRE in a final
concentration of 200 nM for 20 min at 37 °C. After washing with PBS, cells were
resuspended in an appropriate amount of assay buffer and TMRE fluorescence was
assessed via FACS analysis. TMRE was excited at 488 nm and emission was
recorded using a 690/50 bandpass filter. Data were collected from 10 000 cells from
at least three wells per condition.
Lipid peroxidation. For detection of lipid peroxidation in case of HIF-PHD
inhibition, HT-22 cells were seeded in 24-well plates with 55 000 cells per well. To
analyze the effects of PHD1 silencing, cells were transfected with PHD1 siRNA with
22 000 cells per well and grown for 48 h. After treatment with glutamate, cells were
stained with BODIPY 581/591 C11 (Invitrogen) for 1 h at 37 °C in a culture medium
at a final concentration of 2 μM. After collecting and washing once with PBS, cells
were resuspended in an appropriate amount of PBS. Lipid peroxidation was
analyzed by detection of fluorescence shift from green to red via FACS analysis.
Excitation was performed at 488 nm and emission was recorded with a 525/30
bandpass filter (green) and a 690/50 bandpass filter (red). Data were collected from
10 000 cells from at least three wells per condition.
Intracellular soluble ROS. For the analysis of intracellular soluble ROS,
cells were seeded in 24-well plates with 55 000 cells per well and treated with
glutamate and AQ or transfected with ATF4 siRNA for the indicated amount of time.
To analyze the effects of AQ on the formation of soluble ROS in ATF4-silenced cells,
AQ was added immediately after transfection to the culture medium. For detection of
intracellular soluble ROS, the culture medium was replaced by a medium without
serum containing CM-H2DCFDA in a final concentration of 2.5 μM. Cells were
incubated at 37 °C for 30 min followed by 30 min incubation without dye in serum
containing fresh medium. Subsequently, cells were harvested and washed once with
PBS. For detection of green fluorescence, cells were resuspended in a suitable
amount of PBS and analyzed by FACS. DCF was excited at 488 nm and emission
was recorded with a 525/30 bandpass filter. Data were collected from 10 000 cells
from at least three wells per condition.
ATP measurements. For analysis of total ATP levels, cells were seeded in
white 96-well plates (8 000 cells per well) and treated with HIF-PHD inhibitors or
transfected with PHD1 siRNA (3500 cells per well) and grown for 48 h. At indicated
time points of glutamate exposure, ATP levels were analyzed by luminescence
detection with FluoStar according to the manufacturer’s protocol using the ViaLight
plus Kit (Lonza, Verviers, Belgium).
Measurement of cellular OCR. To determine the cellular OCR, cells were
plated in XF96-well microplates (8000 cells per well; Seahorse Bioscience,
Copenhagen, Denmark) and treated with HIF-PHD inhibitors and glutamate. After
appropriate time, OCR measurements were performed as described previously60
with minor modifications. Briefly, the growth medium was washed off and replaced
by ~ 180 μl of assay medium (with 4.5 g/l glucose as the sugar source, 2 mM
glutamine, 1 mM pyruvate, pH 7.35) and cells were incubated at 37 °C for 60 min.
Three baseline measurements were recorded before adding the compounds.
Oligomycin was injected in port A (20 μl) at a final concentration of 3 μM, FCCP
(22.5 μl in port B) at a concentration of 0.4 μM and rotenone/antimycin A (25 μl in
port C) at a concentration of 1 μM. Three measurements were performed after the
addition of each compound (4 min mixing followed by 3 min measuring).
GSH measurement. To determine GSH levels, HT-22 cells were seeded in
6-well plates (180 000 cells per well). After treatment with glutamate and AQ for
indicated amount of time, two wells per condition were harvested by scratching and
washed once with PBS. GSH measurements were performed using GSH Assay Kit
(Cayman Chemical Company, Ann Arbor, MI, USA) following the manufacturer’s
protocol. Briefly, cells were resuspended in MES buffer (0.4 M 2-(N-mopholino)
ethanesulfonic acid, 0.1 M phosphate, 2 mM EDTA, pH 6.0) and homogenized by
sonification. Insoluble fragments were removed by centrifugation at 10 000xg for
15 min. The supernatant was deproteinated by the addition of an equal volume of
metaphosphoric acid (1.25 M). After incubation for 5 min, the mixture was
centrifuged at 17 000xg for 10 min. Subsequently, the supernatant was mixed with a
4 M solution of triethanolamine to increase the pH. After transferring into a 96-well
plate, the assay cocktail containing provided MES buffer, cofactor mixture, enzyme
mixture and Ellman’s reagent was added. Absorbance was measured at 405 nm
after 30 min of incubation. Total GSH amount was determined via standard curve
calculation and normalized to protein content.
Statistical analysis. All data are given as mean±S.D. Statistical comparison
between treatment groups was performed by analysis of variance (ANOVA) followed
by Scheffé’s post hoc test. Calculations were executed with Winstat standard
statistical software (R Fitch Software, Bad Krozingen, Germany).
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